不同危险分层的非瓣膜性房颤患者抗凝治疗现状分析  

A survey on anticoagulation among atrial fibrillation patients with different risk stratification

作　　者：郑文旭[1] 宋明桥[1] 曹秀丽[1] 于蕾[1] 谭丽艳[1] Zheng Wenxu;Song Mingqiao;Cao Xiuli;Yu Lei;Tan Liyan(Department of Neurology,Friendship Hospital of Dalian,Dalian,Liaoning 116001)

机构地区：[1]辽宁省大连市友谊医院神经内科,辽宁大连116001

出　　处：《中外女性健康研究》2018年第18期20-22,67,共4页Women＇s Health Research

摘　　要：目的:通过发放调查问卷了解辽宁省医师尤其是神经内科医师对不同危险分层的非瓣膜性房颤(nVAF)患者抗凝药物的选择,是否依据指南对患者做出正确用药指导。方法:设计调查问卷,从2016年5月开始收集参与医师的基本信息及工作年限。同时给出四份存在nVAF的模拟病例,请医师对四份病例做出自己的用药选择。结果:对于CHADS2-VASc评分≥2的高危nVAF,病例一选择应用抗凝治疗仅为42.79%,病例二为54.15%。对于CHADS2-VASc评分为0分的低危nVAF选择不予治疗仅为21.39%。结论:此次调查问卷结果显示,目前对非瓣膜性房颤患者的用药差异大,规范性差、对高危患者抗凝治疗不足,而对于低危nVAF患者中又存在治疗过度的情况。Objective：To investigate the selection of anticoagulants in treating non Valvular Atrial Fibrillation （nVAP） patients with different risk stratification of physicians, particularly neurologists, in Liaoning. Method： To distribute questionnaires, and collect basic information and the length of employment of physicians who have participated, starting from May 2016. Four simulated cases of nVAF patients are given, and the physicians were asked to select the medications they would use in the treat ment of each case. Results： For high risk nVAF with CHADS2 VASc score ≥2, anticoagulation use rate was 42. 79 % for case 1, 54. 15% for case 2. For low risk nVAF with CHADS2 VASc score of 0, the rate of choosing to give no treatment is 21. 39%. Conclusion： Based on the analysis of the results of this investigation, there exists a vast discrepancy between the choice of medications of different physicians in treating nVAF patients. Anticoagulation for high risk patients is inadequate, and risks of over treatment exist in the cases of low risk nVAF patients.

关 键 词：非瓣膜性房颤 抗凝 调查问卷 

分 类 号：R541.75[医药卫生—心血管疾病]